By simply reacting 2,4-Dihydroxybenzaldehyde (2,4-DHB) with 2-Aminobenzamide (2-AB), a novel Schiff base (E)-2-[(2,4-Dihydroxybenzylidene)amino]benzamide (2,4-DHBAB) has been produced. By employing FT-IR, 1H-NMR and 13C-NMR spectrum investigations, the synthesized Schiff base 2,4-DHBAB was described and its synthesis was validated. By using the well diffusion method and the DPPH method, the antibacterial (Gram positive strains of Staphylococcus aureus, Enterococcus sp., and Gram-negative strains of Escherichia coli, Klebsiella pneumonia), antifungal, and antioxidant properties of the Schiff base 2,4-DHBAB were investigated. The Schiff base 2,4-DHBAB was showing negative antibacterial and antifungal activities against all the tested pathogens at all the concentrations (25, 50, 100 L/mL). The Schiff base 2,4-DHBAB was showing an excellent antioxidant activity (IC50: 55.51) at all five tested concentrations (20, 40, 60, 80, 100 g/mL) compared to standard drug (Ascorbic acid; IC50: 42.31). The potential binding interactions of Schiff base 2,4-DHBAB with the 2019-nCoV RBD/ACE2-B0AT1 complex (PDB code: 6M17) was also investigated.